- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Timm Jessen Joins Cytolon’s Supervisory Board
Cytolon AG announced today that Dr.Timm Jessen has been appointed to the company´s Supervisory Board.
Berlin, January 18th 2010 - Cytolon AG announced today that Timm Jessen has been appointed to the company´s Supervisory Board. Timm Jessen is CEO at a successful biotech company and leader of a consulting company that supports young companies and investors with regard to strategy, business development and scientific marketing. He has a vast experience in leading companies in the healthcare sector.
Thomas Klein, Cytolon’s Founder and Chief Executive Officer, said “we are very satisfied to count on such an outstanding personality from the biotechnology sector. Timm Jessen has a very broad operational experience in developing young companies and will support us in all manners”.
Timm Jessen stated “I am very selective in joining Supervisory Boards, but Cytolon is one of the most interesting start-ups of the last years in Germany. It will be very exciting for me to be part of this young and growing company”.
Biographies of each member of the Supervisory Board are available on our website at www.cytolon.com, the content of which is not part of this press release.
About Cytolon AG:
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area. For more information, please visit the company's Web site at www.cytolon.com.
Contact:
Hanna Dudenhausen – PR/Investor Relations
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 2880
fax: +49 (0) 30 2639 28820
e-mail: hanna.dudenhausen@cytolon.com
web: www.cytolon.com